U.S. markets open in 3 hours 42 minutes

StratoComm Corporation (STCO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00480.0000 (0.00%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0048
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0048 - 0.0048
52 Week Range0.0001 - 0.0090
Avg. Volume15,087
Market Cap981,547
Beta (5Y Monthly)165.65
PE Ratio (TTM)N/A
EPS (TTM)-0.0060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • MarketWatch

    U.S. COVID vaccine supply to be boosted by Merck helping make J&J vaccine

    The U.S. COVID-19 vaccine program is expected to get a welcome jolt on Tuesday in the news that one of the biggest vaccine makers in the world will help make Johnson & Johnson's one-dose jab, potentially doubling the supply from what J&J could achieve on its own.

  • MarketWatch

    Single dose of AstraZeneca or Pfizer COVID-19 vaccine cuts hospitalization risk by more than 80%, study shows

    A single dose of either the AstraZeneca–Oxford vaccine or the Pfizer–BioNTech COVID-19 shot cuts the risk of hospital admission among older adults by more than 80% percent, Public Health England (PHE) said, citing a preprint study. The real world study, which was published on Monday and hasn’t yet been peer-reviewed, showed that protection against any COVID-19 symptoms in those over 70 ranged between 57% and 61% for one dose of the Pfizer–BioNTech shot, and between 60% and 73% for the AstraZeneca–Oxford one four weeks after the first shot.

  • JNJ Stock Rises In Buy Zone As U.S. Begins Distributing Third Covid Vaccine
    Investor's Business Daily

    JNJ Stock Rises In Buy Zone As U.S. Begins Distributing Third Covid Vaccine

    Distribution began Monday for Johnson & Johnson's newly authorized one-shot coronavirus vaccine, leading JNJ stock to pop in early action. McKesson is distributing the J&J vaccine.